Sunshine Biopharma
SBFM
9 hedge funds and large institutions have $337K invested in Sunshine Biopharma in 2025 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 1 closing their positions.
2,918% more capital inflows, than outflows
Capital inflows: $148K | Capital outflows: $4.91K
200% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 1
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
29% more funds holding
Funds holding: 7 → 9 (+2)
2.12% more ownership
Funds ownership: 2.85% → 4.97% (+2.1%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DRW Securities
Chicago,
Illinois
|
+$66.7K |
| 2 |
Two Sigma Investments
New York
|
+$31.7K |
| 3 |
Two Sigma Securities
New York
|
+$25.5K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$21.7K |
| 5 |
Renaissance Technologies
New York
|
+$2.67K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SBI Securities
Tokyo,
Japan
|
-$2.67K |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
-$2.24K |
SBFM Hedge Fund Activity: Q3 2025 in Review
9 of the 7,665 institutional investors tracked by Wall St. Rank reported a position in Sunshine Biopharma (SBFM) for Q3 2025, worth a combined $337K — up 80% from $187K a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new SBFM positions and 1 closed out — a net gain of 2 holders — while 2 added to existing stakes and 1 trimmed.
The largest buyer was DRW Securities, opening a new position worth an estimated $66.7K. The largest seller was SBI Securities, cutting an estimated $2.67K.
- 9 institutional investors held Sunshine Biopharma (SBFM) as of Q3 2025, up from 7 in Q2 2025.
- Funds reported $337K of Sunshine Biopharma stock for Q3 2025, up 80% quarter-over-quarter.
- 3 funds opened new Sunshine Biopharma positions in Q3 2025 and 1 closed out, a net change of +2 holders.
- The largest Sunshine Biopharma buyer in Q3 2025 was DRW Securities, an estimated $66.7K added.
- The largest Sunshine Biopharma seller in Q3 2025 was SBI Securities, an estimated $2.67K sold.
Based on aggregated 13F filings for Q3 2025.